New hope for breast cancer patients: better nausea control during treatment
NCT ID NCT07254416
First seen Dec 16, 2025 · Last updated May 01, 2026 · Updated 17 times
Summary
This study looks at 120 breast cancer patients receiving T-DXd therapy. Half get a standard anti-nausea drug combo, and the other half get a new combo with megestrol acetate. The goal is to see which works better at preventing nausea and vomiting, helping patients stay on treatment and feel better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER PATIENTS TREATED WITH T-DXD are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.